These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38313649)

  • 1. Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma.
    Sun SS; Guo XD; Li WD; Chen JL
    World J Clin Cases; 2024 Jan; 12(2):285-292. PubMed ID: 38313649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization combined with sintilimab and lenvatinib for the treatment of unresectable hepatocellular carcinoma: a retrospective study.
    Shen C; Jiang W; Chen R; Li L; Wu Y; Tan L; Chen Y; Zhang W; Wang Z
    J Cancer Res Clin Oncol; 2024 Sep; 150(9):427. PubMed ID: 39302490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of TACE Combined with Lenvatinib Plus Sintilimab for Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and/or Right Atrium.
    Ning S; Li X; Ma X; Liu J; Chang X
    J Hepatocell Carcinoma; 2023; 10():1511-1525. PubMed ID: 37724186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
    Cao F; Yang Y; Si T; Luo J; Zeng H; Zhang Z; Feng D; Chen Y; Zheng J
    Front Oncol; 2021; 11():783480. PubMed ID: 34988019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
    Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
    Acad Radiol; 2024 Nov; 31(11):4456-4465. PubMed ID: 38760273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study.
    Cai M; Huang W; Liang W; Guo Y; Liang L; Lin L; Xie L; Zhou J; Chen Y; Cao B; Wu J; Zhu K
    Liver Int; 2024 Apr; 44(4):920-930. PubMed ID: 38291865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.
    Zhao L; Chang N; Shi L; Li F; Meng F; Xie X; Xu Z; Wang F
    Heliyon; 2022 Jun; 8(6):e09538. PubMed ID: 35706954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma.
    Xiang YJ; Wang K; Yu HM; Li XW; Cheng YQ; Wang WJ; Feng JK; Bo MH; Qin YY; Zheng YT; Shan YF; Zhou LP; Zhai J; Cheng SQ
    Hepatol Res; 2022 Aug; 52(8):721-729. PubMed ID: 35536197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of transarterial chemoembolization-lenvatinib sequential therapy for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.
    Chen R; Li Y; Song K; Li L; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Apr; 13(2):780-786. PubMed ID: 35557575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
    Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
    Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
    World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study.
    Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    Hepatol Res; 2022 Sep; 52(9):794-803. PubMed ID: 35698267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma.
    Ma KP; Fu JX; Duan F; Wang MQ
    World J Gastrointest Oncol; 2024 Apr; 16(4):1236-1247. PubMed ID: 38660650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.
    Wang L; Wang H; Cui Y; Liu M; Jin K; Xu D; Wang K; Xing B
    Front Oncol; 2023; 13():1115109. PubMed ID: 36874115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of anti-PD-1 monotherapy
    Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
    Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma.
    Gan L; Lang M; Tian X; Ren S; Li G; Liu Y; Han R; Zhu K; Li H; Wu Q; Cui Y; Zhang W; Fang F; Li Q; Song T
    J Hepatocell Carcinoma; 2023; 10():673-686. PubMed ID: 37125392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
    Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
    Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.
    Teng Y; Ding X; Li W; Sun W; Chen J
    Technol Cancer Res Treat; 2022; 21():15330338221075174. PubMed ID: 35313780
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.